BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 15078137)

  • 1. Antiangiogenic therapy in hematologic malignancies.
    Moehler TM; Hillengass J; Goldschmidt H; Ho AD
    Curr Pharm Des; 2004; 10(11):1221-34. PubMed ID: 15078137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiogenesis in hematologic malignancies.
    Moehler TM; Ho AD; Goldschmidt H; Barlogie B
    Crit Rev Oncol Hematol; 2003 Mar; 45(3):227-44. PubMed ID: 12633837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Angiogenesis in patients with hematologic malignancies].
    Mesters RM; PadrĂ³ T; Steins M; Bieker R; Retzlaff S; Kessler T; Kienast J; Berdel WE
    Onkologie; 2001 Sep; 24 Suppl 5():75-80. PubMed ID: 11600818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Angiogenesis and hematologic malignancy].
    Zini JM; Tobelem G
    Bull Cancer; 2007 Jul; 94 Spec No():S241-6. PubMed ID: 17846010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Lenalidomide in hematological malignancies---review].
    Jin X; Zhang YZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Feb; 20(1):205-9. PubMed ID: 22391198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiogenesis and antiangiogenic therapy in hematologic malignancies.
    Dong X; Han ZC; Yang R
    Crit Rev Oncol Hematol; 2007 May; 62(2):105-18. PubMed ID: 17188504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current status of thalidomide in the treatment of cancer.
    Rajkumar SV
    Oncology (Williston Park); 2001 Jul; 15(7):867-74; discussion 877-9. PubMed ID: 11499688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiogenesis in hematologic malignancies.
    Moehler TM; Neben K; Ho AD; Goldschmidt H
    Ann Hematol; 2001 Dec; 80(12):695-705. PubMed ID: 11797109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiogenesis in hematologic malignancies and its clinical implications.
    Yang R; Han ZC
    Int J Hematol; 2002 Apr; 75(3):246-56. PubMed ID: 11999351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines,angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome.
    Mileshkin L; Honemann D; Gambell P; Trivett M; Hayakawa Y; Smyth M; Beshay V; Ritchie D; Simmons P; Milner AD; Zeldis JB; Prince HM
    Haematologica; 2007 Aug; 92(8):1075-82. PubMed ID: 17640854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma.
    Rajkumar SV; Witzig TE
    Cancer Treat Rev; 2000 Oct; 26(5):351-62. PubMed ID: 11006136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone marrow angiogenesis and progression in multiple myeloma: clinical significance and therapeutic approach.
    Eleutherakis-Papaiakovou V; Karali M; Kokkonouzis I; Tiliakos I; Dimopoulos MA
    Leuk Lymphoma; 2003 Jun; 44(6):937-48. PubMed ID: 12854891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The emerging role of angiogenesis inhibitors in hematologic malignancies.
    Giles FJ
    Oncology (Williston Park); 2002 May; 16(5 Suppl 4):23-9. PubMed ID: 12102577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The vascular endothelial growth factor (VEGF) signaling pathway: a therapeutic target in patients with hematologic malignancies.
    Giles FJ
    Oncologist; 2001; 6 Suppl 5():32-9. PubMed ID: 11700390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiangiogenic therapy in myelodysplastic syndromes: is there a role?
    Oh ST; Gotlib J
    Curr Hematol Malig Rep; 2008 Jan; 3(1):10-8. PubMed ID: 20425441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies.
    Podar K; Anderson KC
    Curr Cancer Drug Targets; 2011 Nov; 11(9):1005-24. PubMed ID: 21933109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.
    Du W; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T
    Pathol Int; 2004 May; 54(5):285-94. PubMed ID: 15086832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiogenesis-dependent diseases.
    Folkman J
    Semin Oncol; 2001 Dec; 28(6):536-42. PubMed ID: 11740806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel biologically based therapies for myeloma.
    Anderson KC
    Cancer J; 2001; 7 Suppl 1():S19-23. PubMed ID: 11504280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thalidomide for the treatment of acute myeloid leukemia.
    Steins MB; Bieker R; PadrĂ³ T; Kessler T; Kienast J; Berdel WE; Mesters RM
    Leuk Lymphoma; 2003 Sep; 44(9):1489-93. PubMed ID: 14565649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.